Log in

OTCMKTS:NBIO - Nascent Biotech Stock Price, Forecast & News

$0.12
-0.05 (-29.76 %)
(As of 12/15/2019 12:49 PM ET)
Today's Range
$0.12
Now: $0.12
$0.12
50-Day Range
$0.10
MA: $0.12
$0.17
52-Week Range
$0.05
Now: $0.12
$0.30
Volume500 shs
Average Volume12,116 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company is based in Vero Beach, Florida.

Industry, Sector and Symbol

Industry Agricultural Commodities/Milling
Sub-IndustryN/A
SectorProcess Industries
Current SymbolOTCMKTS:NBIO
CUSIPN/A
CIKN/A
Phone(612) 961-5656

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIO and its competitors with MarketBeat's FREE daily newsletter.


Nascent Biotech (OTCMKTS:NBIO) Frequently Asked Questions

What is Nascent Biotech's stock symbol?

Nascent Biotech trades on the OTCMKTS under the ticker symbol "NBIO."

Has Nascent Biotech been receiving favorable news coverage?

News stories about NBIO stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nascent Biotech earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nascent Biotech.

Who are some of Nascent Biotech's key competitors?

Some companies that are related to Nascent Biotech include BOSWELL J G CO/SH (BWEL), Clariant (CLZNF), Lanxess (LNXSF), LG Chem (LGCLF) and Smurfit Kappa Group (SMFTF).

Who are Nascent Biotech's key executives?

Nascent Biotech's management team includes the folowing people:
  • Mr. Sean Carrick, Pres, Sec. & Director (Age 51)
  • Mr. Lowell Holden, CFO, Chief Accounting Officer & Director (Age 76)
  • Dr. Brandon J. Price, Exec. VP of Bus. Devel. & Director (Age 71)
  • Mr. Onur Boyman, Co-Founder and Director
  • Mr. Jonathan Sprent, Co-Founder and Director

How do I buy shares of Nascent Biotech?

Shares of NBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nascent Biotech's stock price today?

One share of NBIO stock can currently be purchased for approximately $0.12.

What is Nascent Biotech's official website?

The official website for Nascent Biotech is http://www.nascentbiotech.com/.

How can I contact Nascent Biotech?

Nascent Biotech's mailing address is 601 21st St Ste 300, VERO BEACH, FL 32960-0860, United States. The company can be reached via phone at (612) 961-5656.


MarketBeat Community Rating for Nascent Biotech (OTCMKTS NBIO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Nascent Biotech and other stocks. Vote "Outperform" if you believe NBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel